The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction

Neurourology and Urodynamics
Paul AbramsKatherine Warren

Abstract

To assess the use of intravesical gentamicin to treat intractable recurrent urinary tract infections in lower urinary tract dysfunction. A two-center retrospective cohort study of 27 patients treated with intravesical gentamicin was performed over a 2-year period. A treatment protocol was developed, reviewed, and accepted by the clinical effectiveness committee of both hospitals. Patients were taught to instill the gentamicin into the bladder on a nightly basis. Inclusion criteria included failure to respond to standard therapy, having six or more cultured confirmed UTIs over a 12-month period, or at least one hospital admission with sepsis. Serum gentamicin levels were taken after 7 days and the treatment was discontinued if the level was >1 mg/L. Patients were counseled about the limited evidence base for this treatment. Twenty-seven patients have been treated with intravesical gentamicin for an average of 26 months. Seventeen were performing ISC, five had suprapubic catheters, three were voiding, and two had ileal conduits at the time of instituting treatment. All patients started on daily 80 mg gentamicin. Twenty two patients had less frequently occurring infections after starting intravesical gentamicin treatment. Six stop...Continue Reading

References

Apr 8, 2006·The Journal of Urology·William DefoorCurtis Sheldon
Jun 29, 2010·International Journal of Antimicrobial Agents·C van NieuwkoopJ T van Dissel
May 8, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Marco TorellaNicola Colacurci

❮ Previous
Next ❯

Citations

Jan 26, 2018·Female Pelvic Medicine & Reconstructive Surgery·Linda BrubakerJerry L Lowder
Jan 10, 2019·Climacteric : the Journal of the International Menopause Society·Carrie Jung, Linda Brubaker
Jun 1, 2017·Nature Reviews. Urology·Peter Sidaway
Dec 5, 2019·Expert Review of Anti-infective Therapy·Nicola PetrosilloFabrizio Taglietti
Jan 29, 2021·Tzu Chi Medical Journal·Qian-Sheng KeHann-Chorng Kuo
Sep 10, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ioan ScarneciuSorin Lupu
Jan 5, 2022·International Urogynecology Journal·Meghana Reddy, Philippe E Zimmern

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.